Amerigen Pharmaceuticals is a multinational company with established development and manufacturing platforms aimed at providing high-quality generic pharmaceutical products. Its headquarter is based at New Jersey, US. 爱美津制药是一家集研发和制造于一体的跨国公司，旨在向美国提供高质量的仿制药品。总部位于美国新泽西州。 With pharmaceutical assets and science-based expertise in the United States and abroad, Amerigen is able to provide quality products at competitive prices along with unmatched customer service. 凭借在美国和海外的制药资产和技术专家队伍，爱美津致力于提供高品质产品、有竞争力的价格和无以匹敌的客户服务。 At the end of 2007, Amerigen has successfully completed the acquisition of an oral solid dose manufacturing facility in Suzhou Industrial Park, China and established Suzhou Amerigen Pharmaceutical Co., Ltd. 2007年底，爱美津完成了在中国苏州工业园区的口服固体制剂生产厂的收购，并成立了苏州爱美津制药有限公司。 The milestones of Suzhou Amerigen are as follows: 苏州爱美津制药的里程碑如下： 2007 Suzhou Amerigen was established 苏州爱美津成立 2008 First US regulatory filing 首次获得美国法规文件受理 2009 First US FDA PAI & General Inspection 首次美国食品药品监督管理局上市批准和常规检查 2010 Received US FDA approval for bulk tablet manufacturing 获得美国食品药品监督管理局的批准生产大包装片剂 2012 Passed CFDA Re-Inspection (GMP 2010 version) 通过中国食品药品监督管理局再次检查-新版GMP (2010版) 2013 Passed US FDA Inspection –Recommended approvals on four ANDAs 通过美国食品药品监督管理局检查- 4个简化新药被推荐批准 2014 Launched US Product and re-introduced China Products 产品在美国市场上市, 中国市场产品恢复生产。 2015 Passed US FDA Inspection on Data Integrity 通过美国食品药品监督管理局针对数据完整性的检查 Amerigen sincerely welcome you to join its elite staff to build a great generic company. 爱美津真诚欢迎药业精英加盟，共同缔造爱美津的美好未来。